4-[1-(Ethylsulfonyl)-4-piperidyl]morpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-[1-(Ethylsulfonyl)-4-piperidyl]morpholine
• 英文别名: 4-(1-ethylsulfonylpiperidin-4-yl)morpholine
• 化学式: C₁₁H₂₂N₂O₃S
• 分子量: 262.37
• InChiKey: OAKGQSORQLNTML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  58.2
• 氢给体数：
  0
• 氢受体数：
  5

文献信息

• PYRROLOPYRIMIDINE DERIVATIVE, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE COMPRISING SAME AS ACTIVE INGREDIENT
  申请人：Voronoi Co., Ltd.

  公开号：EP3915991A1

  公开（公告）日：2021-12-01

  The present invention relates to a pyrrolopyrimidine derivative, and a pharmaceutical composition for preventing or treating protein kinase-related disease comprising the same as an active ingredient. The pyrrolopyrimidine derivative has excellent inhibitory activity against various protein kinases comprising LRRK2, and has an excellent effect of inhibiting the proliferation of triple-negative breast cancer cells. Therefore, the pharmaceutical composition comprising the pyrrolopyrimidine derivative as an active ingredient may be useful for the treatment or prevention of protein kinase-related diseases, in particular, cancer, degenerative brain diseases, and inflammatory diseases, and specifically, may be useful for the treatment of triple-negative breast cancer.

  本发明涉及一种吡咯并嘧啶衍生物，以及以其为活性成分的用于预防或治疗蛋白激酶相关疾病的药物组合物。该吡咯并嘧啶衍生物对包括 LRRK2 在内的多种蛋白激酶具有极佳的抑制活性，并对三阴性乳腺癌细胞的增殖具有极佳的抑制效果。因此，包含吡咯并嘧啶衍生物作为活性成分的药物组合物可用于治疗或预防蛋白激酶相关疾病，尤其是癌症、脑退化性疾病和炎症性疾病，特别是可用于治疗三阴性乳腺癌。